Advertisement
Advertisement
U.S. markets open in 5 hours 22 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Matinas BioPharma Holdings Inc (6LJ.BE)

Berlin - Berlin Delayed Price. Currency in EUR
0.1230+0.0020 (+1.65%)
As of 09:10AM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.1210
Open0.1230
Bid0.0970 x N/A
Ask0.1490 x N/A
Day's Range0.1230 - 0.1230
52 Week Range0.1160 - 0.9034
VolumeN/A
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateOct 31, 2023 - Nov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 6LJ.BE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Matinas BioPharma to Present at Two Investment Conferences in October 2023

      BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences: Dawson James Small Cap Growth Confer

    • GlobeNewswire

      Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek

      BEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its proprietary lipid nanocrystal (LNC) platform technology, announces that MAT2203, its oral LNC formulation of amphotericin B (AMB), will be featured in an oral company pipeline presentation at IDWeek, being held October 11-15 at the Boston Convention and Exhib

    • GlobeNewswire

      Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency

      BEDMINSTER, N.J., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, today announced that it has received a deficiency letter ("Letter") from NYSE American LLC ("NYSE American" or the "Exchange") stating that the Company is not in compliance with the continued listing standards as s

    Advertisement
    Advertisement